Allogeneic sibling transplantation for severe aplastic anemia
Institution/study . | Years of study . | N . | Age, y (median in y) . | Graft rejection/failure, % . | Acute GVHD,*% . | Chronic GVHD, % . | Actuarial survival, % . |
|---|---|---|---|---|---|---|---|
| IBMTR92 | 1988-1992 | 471 | 20 (1-51) | 16 | 19 | 32 | 66 at 5 y |
| Vienna93 | 1982-1996 | 20 | 25 (17-37) | 0 | 26 | 53 | 95 at 15 y |
| EBMT94 | 1991-1998 | 71 | 19 (4-46) | 3 | 30 | 35 | 86 at 5 y |
| Seoul95 | 1990-1999 | 22 | 22 (14-43) | 5 | 10 | 33 | 95 at 5 y |
| Seoul96 | 1990-2001 | 64 | 28 (14-43) | 18 | 31 | 19 | 79 at 6 y |
| Hamburg97 | 1990-2001 | 21 | 25 (7-43) | 5 | 5 | 5 | 86 at 5 y |
| Paris98 | 1994-2001 | 33 | 20 (8-42) | 6 | 0 | 42 | 94 at 5 y |
| Sao Paulo99 | 1993-2001 | 81 | 24 (3-53) | 22 | 37 | 39 | 56 at 6 y |
| Taipei100 | 1985-2001 | 79 | 22 (4-43) | 8 | 7 | 35 | 74 at 5 y |
| Tunis101 | 1998-2001 | 31 | 19 (4-39) | 16 | 11 | 3 | 86 at 2 y |
| Seoul102 | 1995-2001 | 113 | 28 (16-50) | 15 | 11 | 12 | 89 at 6 y |
| London103 | 1989-2003 | 33 | 17 (4-46) | 24 | 14 | 4 | 81 at 5 y |
| Seattle104,105 | 1988-2004 | 94 | 26 (2-59) | 4 | 24 | 26 | 88 at 6 y |
| Mexico City106 | 2000-2005 | 23 | 25 (4-65) | 26 | 17 | 26 | 88 at 4 y |
Institution/study . | Years of study . | N . | Age, y (median in y) . | Graft rejection/failure, % . | Acute GVHD,*% . | Chronic GVHD, % . | Actuarial survival, % . |
|---|---|---|---|---|---|---|---|
| IBMTR92 | 1988-1992 | 471 | 20 (1-51) | 16 | 19 | 32 | 66 at 5 y |
| Vienna93 | 1982-1996 | 20 | 25 (17-37) | 0 | 26 | 53 | 95 at 15 y |
| EBMT94 | 1991-1998 | 71 | 19 (4-46) | 3 | 30 | 35 | 86 at 5 y |
| Seoul95 | 1990-1999 | 22 | 22 (14-43) | 5 | 10 | 33 | 95 at 5 y |
| Seoul96 | 1990-2001 | 64 | 28 (14-43) | 18 | 31 | 19 | 79 at 6 y |
| Hamburg97 | 1990-2001 | 21 | 25 (7-43) | 5 | 5 | 5 | 86 at 5 y |
| Paris98 | 1994-2001 | 33 | 20 (8-42) | 6 | 0 | 42 | 94 at 5 y |
| Sao Paulo99 | 1993-2001 | 81 | 24 (3-53) | 22 | 37 | 39 | 56 at 6 y |
| Taipei100 | 1985-2001 | 79 | 22 (4-43) | 8 | 7 | 35 | 74 at 5 y |
| Tunis101 | 1998-2001 | 31 | 19 (4-39) | 16 | 11 | 3 | 86 at 2 y |
| Seoul102 | 1995-2001 | 113 | 28 (16-50) | 15 | 11 | 12 | 89 at 6 y |
| London103 | 1989-2003 | 33 | 17 (4-46) | 24 | 14 | 4 | 81 at 5 y |
| Seattle104,105 | 1988-2004 | 94 | 26 (2-59) | 4 | 24 | 26 | 88 at 6 y |
| Mexico City106 | 2000-2005 | 23 | 25 (4-65) | 26 | 17 | 26 | 88 at 4 y |
In contrast to Table 1, response rates are not provided because, in surviving patients who do not experience primary graft rejection or secondary graft failure, full hematologic recovery with donor hematopoiesis is anticipated. Only studies reporting at least 20 patients are tabulated
GVHD indicates graft-versus-host disease; IBMTR, International Blood and Marrow Transplant Registry; and EBMT, European Group for Bone Marrow Transplant
Results are generally for grades II to IV and patients at risk